^
Association details:
| Biomarker: | CLDN18.2 expression |
|---|---|
| Cancer: | Gastroesophageal Junction Adenocarcinoma |
| Drug: | IBI-345 (CLDN18.2-targeted CAR-T immunotherapy) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1054P - A phase Ia study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of a modular CLDN18.2-targeting PG CAR-T therapy (IBI345) in patients with CLDN18.2+ solid tumors
Published date:
10/16/2023
Excerpt:
1 EGJC pt achieved PR and 2 pts (1 GC, 1 PC) achieved SD….IBI345 demonstrated a manageable safety profile and preliminary efficacy in patients with CLDN18.2+ advanced solid tumors.
Trial ID:
